ProKidney Corp.
NCM: PROKLive Quote
📈 ZcoreAI Score
Our AI model analyzes ProKidney Corp.'s price action across multiple timeframes using regression channels and statistical scoring.
Get PROK Z-Score →About ProKidney Corp.
Healthcare
Biotechnology
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
📊 Fundamental Analysis
ProKidney Corp. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 196.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -43.2%, which indicates that capital utilization is currently under pressure.
At a current price of $1.95, PROK currently sits at the 21st percentile of its 52-week range (Range: $0.54 - $7.13).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$587.40M
Trailing P/E
--
Forward P/E
-2.67
Beta (5Y)
1.86
52W High
$7.13
52W Low
$0.54
Avg Volume
843K
Day High
Day Low